Hypersensitivity reactions in ovarian cancer patients receiving paclitaxel.
OBJECTIVE
The aim of this study was to describe a rapid retreatment strategy in patients with paclitaxel hypersensitivity reactions.


METHODS
A retrospective review of all patients receiving standard 3-hour infusion paclitaxel-based chemotherapy after proper premedication at the Department of Gynecologic Oncology, University of Bari between 1995 and 1998, was performed. All patients who developed hypersensitivity reactions to paclitaxel were identified and their treatment course and outcome were reviewed. A review of the literature on this subject is also presented.


RESULTS
Eighty-six women were treated with 461 cycles of paclitaxel-based chemotherapy at our Unit. Twelve patients (14%) developed hypersensitivity reactions. All had received standard premedication consisting of corticosteroids and hystamine blockers. Hypersensitivity reactions consisted of isolated face flushes (3 patients), dyspnea and chest tightness (4 patients) or bronchospasm (5 patients). Eleven patients were rechallenged with the original paclitaxel solution starting at a slower rate after a second premedication with a double dosage of steroids. None of these patients had reactions in subsequent courses. Only one patient (the first of this series treated in February 1995), was retreated 5 days later under strict monitoring in intensive care unit.


CONCLUSIONS
Retreatment with the original paclitaxel solution is safe in almost all patients with hypersensitivity reactions. The drug should be administered within the next 24 hours with a new premedication protocol.
Cormio
G
G
Department of Gynecologic Oncology, University of Bari, Italy.
Di Vagno
G
G
Melilli
G A
GA
Cazzolla
A
A
Di Gesù
G
G
Carriero
C
C
Cramarossa
D
D
Loverro
G
G
Selvaggi
L
L
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000209:etiology*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000009:adverse effects*; D012189:Retrospective Studies
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel